Kniggendorf et al., 2020 - Google Patents
Degeneração macular relacionada à idade: revisão das terapias atuais e novos tratamentosKniggendorf et al., 2020
View HTML- Document ID
- 7504077377010908401
- Author
- Kniggendorf V
- Dreyfuss J
- Regatieri C
- Publication year
- Publication venue
- Arquivos Brasileiros de Oftalmologia
External Links
Snippet
Age-related macular degeneration is the leading cause of vision loss in elderly individuals, as well as a medical and socio-economic challenge. The treatment of dry age-related macular degeneration is based on vitamin supplementation. New treatment studies are …
- 206010064930 Age-related macular degeneration 0 abstract description 141
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kniggendorf et al. | Age-related macular degeneration: a review of current therapies and new treatments | |
| US10253111B2 (en) | Methods and compositions relating to anti-Chi3l1 antibody reagents | |
| CN107530419A (en) | Treat the combination treatment of disease | |
| JPWO2019189780A1 (en) | Pharmaceutical composition for the treatment and / or prevention of cancer | |
| KR20160108566A (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
| CA2573821A1 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
| US11235043B2 (en) | Vaccines against antigens involved in therapy resistance and methods of using same | |
| CN104080471A (en) | Antibodies and methods for Wnt pathway-related diseases | |
| KR20190053909A (en) | Combination therapy of antibodies and checkpoint immunosuppressants | |
| US10934331B2 (en) | Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells | |
| WO2020015703A9 (en) | Drug combination of quinoline derivative and antibody | |
| US11666659B2 (en) | Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof | |
| JP2021511372A (en) | How to Treat Cancer with Antibodies to TIM3 | |
| Kim et al. | Therapeutic options under development for nonneovascular age-related macular degeneration and geographic atrophy | |
| KR20180073680A (en) | Compositions comprising IL6R antibodies for treatment of uveitis and macular edema and methods of using same | |
| JP2023517534A (en) | Pharmaceutical composition for treating cancer, comprising fusion protein containing IL-2 protein and CD80 protein, and anticancer agent | |
| Gacche | Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives | |
| CN109311972A (en) | For treating the method and composition of the sensitive and intractable chylous diarrhea of chylous diarrhea, non-chylous diarrhea seitan | |
| JP2021523153A (en) | Polypharmacy for use in the treatment of cancer | |
| CN116782934A (en) | Anti-galectin 9 antibodies and their use in the treatment of ocular melanoma | |
| Kniggendorf et al. | Degeneração macular relacionada à idade: revisão das terapias atuais e novos tratamentos | |
| AU2005325227B2 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| US20230183323A1 (en) | Methods for preventing, reversing or treating a covid-19 infection | |
| JP2017502025A (en) | Compositions and methods for treating sarcomas | |
| Stewart | Future treatments of diabetic retinopathy: pharmacotherapeutic products under development |